Abstract | OBJECTIVE: Responses to therapies, either with regard to toxicities or efficacy, are expected to involve complex relationships of gene products within the same molecular pathway or functional gene set. Therefore, pathways or gene sets, as opposed to single genes, may better reflect the true underlying biology and may be more appropriate units for analysis of pharmacogenomic studies. Application of such methods to pharmacogenomic studies may enable the detection of more subtle effects of multiple genes in the same pathway that may be missed by assessing each gene individually. METHODS: RESULTS: CONCLUSION: In summary, results from the gene set analysis of pyrimidine and purine therapies, used often in the treatment of various cancers, provide novel insight into the relationship between genomic variation and drug response.
|
Authors | Brooke L Fridley, Anthony Batzler, Liang Li, Fang Li, Alice Matimba, Gregory D Jenkins, Yuan Ji, Liewei Wang, Richard M Weinshilboum |
Journal | Pharmacogenetics and genomics
(Pharmacogenet Genomics)
Vol. 21
Issue 11
Pg. 701-12
(Nov 2011)
ISSN: 1744-6880 [Electronic] United States |
PMID | 21869733
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimetabolites
- Antineoplastic Agents
- Purines
- Pyrimidines
- Deoxycytidine
- Thioguanine
- pyrimidine
- purine
- Gemcitabine
|
Topics |
- Antimetabolites
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Area Under Curve
- Cell Line, Tumor
- Deoxycytidine
(analogs & derivatives, pharmacology, therapeutic use)
- Genes, Neoplasm
(genetics)
- Humans
- Neoplasms
(drug therapy, genetics)
- Phenotype
- Purines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Reproducibility of Results
- Thioguanine
(pharmacology, therapeutic use)
- Gemcitabine
|